Media Release
Basel, Switzerland – March 21, 2017

PIQUR Strengthens Management Team with Key Hire, Melanie Rolli

Dr. Melanie Rolli joins PIQUR as new Chief Medical Officer

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that it has strengthened its management team with the appointment of Dr. Melanie Rolli as Chief Medical Officer.

“We are very pleased to welcome Melanie Rolli to PIQUR as our Chief Medical Officer,” said Vladimir Cmiljanovic, CEO of PIQUR Therapeutics. “Melanie’s broad research and drug development expertise and proven leadership skills will be instrumental to the future success of PIQUR.”

Melanie Rolli brings more than a decade of industry experience and senior responsibilities in global development, medical affairs and patient safety. She joins PIQUR from Novartis Pharma, where she held various positions with increasing responsibilities over the last 14 years, most recently as Global Head Medical Safety. Prior to joining Novartis, she worked as a medical doctor at the University Hospital in Mannheim and as a basic researcher in academic settings in Germany and at the Scripps Research Institute, USA.

PIQUR’s management team now consists of the following members:

- **Dr. Vladimir Cmiljanovic**, Chief Executive Officer
- **Dr Melanie Rolli**, Chief Medical Officer
- **Dr. Dorianno Fabbro**, Chief Scientific Officer
- **Hervé Girsault**, Chief Business Officer

"I am excited to join the talented and passionate team at PIQUR at this stage, and I look forward to helping the team advance the development of new and innovative cancer therapies for patients in need," said Melanie Rolli.

***ENDS***
Notes to Editors

Contacts
Media Relations:
Tatsuo Satoh
Head Communications
T: +41 61 633 29 38
M: +41 78 819 17 44
tatsuo.satoh@piqur.com

About PQR309
PIQUR’s lead compound, PQR309, is an oral, brain-penetrant, dual inhibitor of the PI3K/mTOR pathway, which is activated in 60-80% of human cancers. Unlike most of its competitors, PQR309 crosses the blood-brain barrier, expanding its use to malignant diseases involving the brain. Preclinical and Phase 1 studies have shown PQR309 to have a favorable safety, tolerability and pharmacokinetic profile. In addition, PQR309 has shown both preclinical activity in various tumor models and clinical activity in Phase 1 and 2 studies. In November 2016, PQR309 was granted Orphan Drug Designation for PCNSL by the US FDA.

PQR309 is currently being investigated in five Phase 1 and 2 clinical studies in advanced solid tumors (NCT02483858), relapsed or refractory lymphoma (NCT02249429), relapsed or refractory PCNSL (NCT02669511) and progressive glioblastoma multiforme (NCT02850744). In addition, the PIQHASSO Phase 1/2b study investigates PQR309 in combination with Eisai’s Eribulin in metastatic HER2-negative and triple-negative breast cancer (NCT02723877).

About PIQUR Therapeutics
PIQUR Therapeutics is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on the inhibition of lipid kinase (PI3K) and mTOR. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR holds a worldwide exclusive license on the intellectual property rights for PQR309 and related series of analogues, for development and commercialization. www.piqur.com